The Food and Drug Administration has cleared the startup to market $199 genetic tests that will tell consumers not whether they have a condition like Parkinson's or Alzheimer's, but how likely they might be to get it. In February 2015, the FDA cleared 23andMe to provide consumers with information about genes they might carry that might affect their future children. The new FDA approval will allow 23andMe to tell consumers about their risk for 10 conditions. This won't tell a person whether they have a disease, but whether they are at risk of getting it. As part of its approval process for these new tests, 23andMe monitored used of its product by 25,000 people in the U.K., where the Parkinson's and Alzheimer's tests were available.

Source: Forbes April 06, 2017 19:18 UTC